EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
7:00am - 8:00am 60 mins
Info
Continental Breakfast - Hilton Union Square

Hilton Union Square, Grand Ballroom

7:00am - 6:00pm 660 mins
Info
Registration and Tabletop Exhibit Open - Hilton Union Square

Hilton Union Square, Plaza A, Lobby Level

8:00am - 8:55am 55 mins
Info
Cell and gene therapy: The financing surge - Hilton Union Square
  • Moderator Reni Benjamin - Managing Director and Senior Biotechnology Analyst, Raymond James
  • Panelist Vered Caplan - CEO, Orgenesis
  • Panelist Maha Katabi - Co-Founder and Managing Partner, Oxalis Capital
  • Panelist Geoff MacKay - President and CEO, Avrobio Inc.
  • Panelist Scott Requadt - Venture Partner, Blackstone

Hilton Union Square, Yosemite A

The pending clinical realization of curative and disruptive therapeutic products has resulted in a poignant shift in the investment and financial landscape. For companies engaged in the development of Gene and Cell Therapies, a ready supply of cash and an up-swell in enthusiasm for the sector has resulted in historical fundraising. We have seen the onset of “mega-rounds” with a $50–200M Series A. In parallel, there has been a shift in the M&A landscape, where recently companies with little platform validation have been acquired at valuations in the high hundreds of millions. These shifts bring forward some key questions on the future of regenerative medicine/advanced therapies. What are the opportunities and what do investors need to understand to ensure these therapies thrive in the current environment?

8:00am - 8:55am 55 mins
Info
Reexamining Alzheimer’s: Is it a singular disease? - Hilton Union Square
  • Moderator Kim Goh - Principal, ClearView Healthcare Partners
  • Panelist Casey Lynch - CEO, Cortexyme
  • Panelist Kenneth I. Moch - President and CEO, Cognition Therapeutics, Inc.
  • Panelist Barbara Tate - Venture Partner, Dementia Discovery Fund and SV Life Sciences
  • Panelist John Vandermosten - Senior Biotech Analyst, Zacks

 Hilton Union Square, Yosemite C

The medical community is shifting its perspective on Alzheimer’s disease from a singular disease to a complex web of Alzheimer’s disease-related dementias, and investors need to do the same. By dissecting and appreciating the complexity of the disease, new players with novel approaches to the treatment and management of these conditions are emerging including the need to rethink the targets for drug therapies. Even regulatory agencies are taking a more critical look at the downstream complexities in regard to clinical trials and biomarkers while pushing forward solutions to bolster clinical development. Other organizations must take the same approach and recalibrate their thinking of Alzheimer’s as a singular disease. Join us as we discuss what we’ve learned over the past year and the future of clinical development for Alzheimer’s disease.

8:00am - 6:00pm 600 mins
Info
One-to-one meetings - Hilton Union Square

Hilton Union Square, Grand Ballroom

8:30am - 12:00pm 210 mins
Info
Company Presentations - Hilton Union Square

Hilton Union Square,
Yosemite A and C
Franciscan A, B, C and D

12:00pm - 1:45pm 105 mins
Info
Lunch Plenary: The financing frenzy: Is it truly the best of times? - Hilton Union Square
  • Moderator Steve Abrams - Partner, Hogan Lovells US LLP
  • Panelist Eric Aguiar - Partner, Aisling Capital
  • Panelist Gabriel Cavazos - Managing Director, Leerink Partners LLC
  • Panelist Kimberly Ha - CEO and Founder, KKH Advisors
  • Panelist Philippe Lopes-Fernandes - Senior VP, Global Head of Business Development and Alliance Management, Merck KGaA, Darmstadt, Germany
  • Panelist Marian Nakada - VP, Venture Investments, Johnson & Johnson Innovation - JJDC

Hilton Union Square, Imperial Ballroom

It has been quite a year for biotech financing with a record number of IPOs (48 by the end of Q3) and a record year for venture investments ($29.5 billion by October 29, 2018, according to Pitchbook). Companies are going public earlier, there is a significant increase in the size of A rounds creating an increase in access to capital and high valuations. Venture firms are raising new mega funds and are flush with new capital that they need to put to work. Pharma companies in the meantime are questioning the high potential cost of their next M&A and collaboration deals. Will the increasingly solid fundamentals of the biotech sector protect it from the challenges we see the overall market facing? What comes next? Will money continue to flow into this space?

1:45pm - 5:30pm 225 mins
Info
Company Presentations - Hilton Union Square

Hilton Union Square,
Yosemite A and C
Franciscan A, B, C and D

4:30pm - 5:30pm 60 mins
Info
To spend or not to spend: Investing for commercial success as an emerging company - Hilton Union Square
  • Facilitator Naveen Murthy - Managing Director, Syneos Health

 Hilton Union Square, Franciscan A

Whether or not the plan is to partner, out-license or go it alone, executives at emerging companies need to understand what levels of spend are appropriate to prepare a product for a successful launch. Many clinical-stage companies find themselves either underfunding and subsequently underperforming in the market, or overfunding and incurring costs that do not add incremental value to commercial success. A strategic analysis of influential factors, such as level of development risk, corporate strategy, customer base characteristics and competitive landscape can help these companies determine whether to spend more or less, earlier or later in the process as they bring their product to market.

Space is limited – Add to your partneringONE agenda to reserve your spot! 

4:30pm - 5:15pm 45 mins
Info
The shifting model: How new era, patient-led collaborations are transforming drug discovery and development in rare disease, and beyond - Hilton Union Square
  • Moderator Walt Kowtoniuk - Principal, Third Rock Ventures
  • Panelist Tauhid Ali - VP and Head, Takeda TAK-celerator
  • Panelist Daniel Fischer - Founder and CEO, Tevard Biosciences
  • Panelist Neil Kumar - CEO and Founder, BridgeBio
  • Panelist Christine Waggoner - President and Co-Founder, Cure GM1 Foundation

 Hilton Union Square, Imperial Ballroom

It used to be that patient groups were involved at the beginning (advocating for research) and the end (demanding access) of drug discovery and development. Today—enabled by the emergence of and access to new technologies and spurred on by the shortcomings of traditional drug discovery and development—rare disease communities are aggregating data, establishing collaborative research networks and nimble partnerships with industry, and even creating companies to accelerate the speed and enhance the productivity of drug discovery. Hear about who and what is behind these models, and implications even beyond rare disease, in particular for investors, from expert stakeholders in a stand-and-deliver format that will keep you energized and engaged.

Showing of Streams